Literature DB >> 2555803

Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers.

U Saarialho-Kere1, M J Mattila, T Seppälä.   

Abstract

Psychomotor performance related to driving and occupational skills was measured double-blind and cross-over in 9 healthy volunteers before and 1.5, 3 and 4.5 hr after intramuscular injection of oxycodone (0.13 mg/kg), oral diphenhydramine (100 mg) and placebo. The effects of oxycodone on performance peaked at 1.5 hr when it prolonged reaction time and impaired vigilance, attention, body balance and coordination of extraocular muscles. The subjects assessed themselves mentally slow, muzzy and impaired by performance on visual analogue scales still 3 hr after injection. Critical flicker discrimination was impaired and some respiratory depression still present at 4.5 hr after administration. Oxycodone elevated plasma prolactin at 1.5 and 3 hr while growth hormone levels remained unaffected. We conclude that the profile of psychomotor decrement produced by this mu-opioid agonist closely resembles that of agonist-antagonist analgesics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555803     DOI: 10.1111/j.1600-0773.1989.tb01168.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  11 in total

1.  The effects of acute and chronic steady state methadone on memory retrieval in rats.

Authors:  Erin Cummins; Craig P Allen; Alexander Ricchetti; Emily Boughner; Kayla Christenson; Megan Haines; Cheryl L Limebeer; Linda A Parker; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2012-01-19       Impact factor: 4.530

2.  The pharmacokinetics of oxycodone after intravenous injection in adults.

Authors:  R Pöyhiä; K T Olkkola; T Seppälä; E Kalso
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 3.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

4.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.

Authors:  Julia Riley; Joy R Ross; Dag Rutter; Athol U Wells; Katherine Goller; Ron du Bois; Ken Welsh
Journal:  Support Care Cancer       Date:  2005-06-11       Impact factor: 3.603

5.  Subjective and behavioral responses to intravenous fentanyl in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; J G Zaragoza; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

Authors:  William W Stoops; Kevin W Hatton; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2010-07-28       Impact factor: 4.530

7.  Subjective, behavioral and physiological responses to intravenous meperidine in healthy volunteers.

Authors:  J P Zacny; J L Lichtor; W Binstock; D W Coalson; T Cutter; D C Flemming; B Glosten
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 8.  Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children.

Authors:  K T Olkkola; K Hamunen; E L Maunuksela
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers.

Authors:  Nathalie V Goletiani; Jack H Mendelson; Michelle B Sholar; Arthur J Siegel; Alicja Skupny; Nancy K Mello
Journal:  Pharmacol Biochem Behav       Date:  2007-02-20       Impact factor: 3.533

Review 10.  Oxycodone: a pharmacological and clinical review.

Authors:  A Ordóñez Gallego; M González Barón; E Espinosa Arranz
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.